Core Insights - QIAGEN has launched 100 new assays for its QIAcuity digital PCR platform, targeting applications in cancer research, genetic disorders, infectious disease surveillance, and environmental monitoring [1][2][3] - The company has exceeded its 2024 goal by launching over 130 new assays this year, contributing to a total of more than 2,300 validated assays [2] Product Development - The new assays include dPCR LNA Mutation and dPCR CNV Probe Assays, focusing on cancer-related mutations and copy number variations in genes associated with various cancers [3][4] - dPCR Microbial DNA Detection Assays are designed to identify pathogens linked to infectious diseases and antibiotic resistance, as well as animal and plant diseases [4] Market Adoption - QIAcuity digital PCR has seen strong adoption, with over 2,000 placements by the end of 2023 and citations in over 450 publications, serving key customers in pharmaceuticals, academia, and diagnostics [5] Technological Advancements - The QIAcuity platform utilizes nanoplates for sample partitioning, allowing simultaneous reading of reactions, which reduces processing time from six hours to two [6] - The platform is available in one-, four-, and eight-plate versions, catering to various laboratory sizes and throughput needs [6] Future Plans - An in-vitro diagnostic version of QIAcuity is set to launch in fall 2024, aimed at clinical applications such as diagnosing infectious diseases and monitoring cancer [7] - QIAGEN is collaborating with pharmaceutical companies to develop companion diagnostics using the QIAcuity platform [7]

QIAGEN's (QGEN) business is expected to get a boost from its growing molecular diagnostic market, expanded test menu and growth-driving strategic collaborations. Yet, a challenging macro environment and an intensely competitive market may dent its results of operations. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving Growth for QGEN Stock QIAGEN offers one of the broadest portfolios of molecular technologies for healthcare. Its range of assays for diseases and biomarkers speeds up and si ...

QIAGEN N.V. (QGEN) announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a leading vaccines and diagnostics supplier to the Brazilian Ministry of Health. Initiated in 2009, the expanded collaboration allows Bio-Manguinhos to launch an advanced PCR (Polymerase Chain Reaction)-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus, a capability previously unavailable in Brazil's blood donation program. The recent development will also support ep ...

Venlo, the Netherlands, Rio de Janeiro, Brazil, Sept. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its strategic partnership with BioManguinhos/Fiocruz, the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinho ...

Venlo, the Netherlands, Sept. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes which can play a role in the diagnosis of Alzheimer's disease. This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping. The panel will be int ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of the new senior ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") announces certain terms of the new senior, unsecured net sha ...

QIAGEN N.V.'s (QGEN) growth is backed by its robust progress in expanding the test menu options. The company's expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to macroeconomic volatilities and currency fluctuations, which can adversely affect its financial results. Year to date, this Zacks Rank #3 (Buy) stock has risen 0.9% compared with 10.5% growth of the industry. The S&P 500 composite has witnessed an 18.1% rise in ...

Company Overview - QIAGEN N.V. is a leading provider of technologies and products for the separation, purification, and handling of nucleic acids DNA/RNA, based in Venlo, the Netherlands [11] - The company offers over 500 proprietary, consumable products and automated solutions for sample collection, focusing on pre-analytical sample preparation and molecular diagnostics [11] Investment Ratings - QGEN currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B [12] - The stock has a Momentum Style Score of A, indicating strong upward price movement, with shares increasing by 12% over the past four weeks [12] Earnings Estimates - Seven analysts have revised their earnings estimates upwards for QGEN in the last 60 days for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.03 to $2.14 per share [12] - QGEN has an average earnings surprise of 2.6%, suggesting a positive outlook on earnings performance [12] Investment Consideration - With a solid Zacks Rank and high Momentum and VGM Style Scores, QGEN is recommended for investors' consideration [13]

QIAGEN N.V.'s (QGEN) second-quarter 2024 adjusted earnings per share (EPS) were 55 cents, the same at the constant exchange rate (CER). The reported figure increased 7.8% from the 2023 comparable figure and topped the Zacks Consensus Estimate by 5.8%. The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others. On a GAAP basis, the lo ...